[go: up one dir, main page]

AR005974A1 - Derivado peptido; composicion farmaceutica que contiene para tratar enfermedades; el uso del derivado peptido. - Google Patents

Derivado peptido; composicion farmaceutica que contiene para tratar enfermedades; el uso del derivado peptido.

Info

Publication number
AR005974A1
AR005974A1 ARP970100731A ARP970100731A AR005974A1 AR 005974 A1 AR005974 A1 AR 005974A1 AR P970100731 A ARP970100731 A AR P970100731A AR P970100731 A ARP970100731 A AR P970100731A AR 005974 A1 AR005974 A1 AR 005974A1
Authority
AR
Argentina
Prior art keywords
formula
group
peptide derivative
piperazinyl
phenyl
Prior art date
Application number
ARP970100731A
Other languages
English (en)
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603855.9A external-priority patent/GB9603855D0/en
Priority claimed from GBGB9620819.4A external-priority patent/GB9620819D0/en
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of AR005974A1 publication Critical patent/AR005974A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Trata sobre derivados péptidos de uso farmacéutico de fórmula: P-R1-R2-R3-R4, donde P es un residuo hidrófobo; R1 es una secuencia de 5 L-aminoácidos y R3 es un solo L-aminoácido o R1 es una secuencia de 3L- aminoácidos; R2 esun grupo de fórmula (II) o fórmula (III), donde Ra y Rbse seleccionan independientemente entre hidrógeno y alquilo (C1-C4) y A es metileno u oxígeno y R4 es OH, NH2 o NRcRd donde Rc se selecciona entrealquilo (C1-C4), 2-carbamoilciclopentilo,2- piridilmetilo, 4- carbamoilciclohexilmetilo, 3-carbamoilfenilo, 4-carbamoilfenilo, 4-(carbamoilmetil)fenilo, 4-(carboximetil)fenilo, 4-(metoxicarbonilmetil)-fenilo, 2-morfolinoetil y un grupo de fórmula -A1-G1, donde A1 esalquileno (C3-C7) oA1 se selecciona entre: (1) un grupo de fórmula -A2-B2 donde A2 es p-fenileno o 1,4-ciclohexileno y B2 es (C1-C4)alquileno o A2 es metileno y B2es p-fenilenoo 1,4-ciclohexileno; y (2) un grupo de fórmula -A3-B3-C3 donde A3 es m etileno, B3 es p-fenileno o 1,4ciclohexileno y C3 es alquileno (C1-C3); yG1 es un grupo de fórmula -N=C[N(Rp)2]2 donde cada Rp se selecciona independientemente entre hidrógeno, metilo, etilo y propilo; o A1 es un grupodefórmula -A4-B4 do nde A4 es p-fenilo y B4 es -CH2-CO y G1 es 2-morfolinoetilo o 4-[2-(2-hidroxietoxi)etil]piperazin-1-ilo; y Rd es hidrógeno o alquilo(C1-C4) o R4 es 1-piperazinilo, 4-metil-1-piperazinilo, 4-amidino-1- piperazinilo,4(2-(2-hidroxietoxi)etil )-1-piperazinilo, 1-piperidilo o 4-sustituido-1-piperidilo donde el 4-sustituyente se selecciona entre carboxi, carbomoilo, N-(2-aminoetil)carbamoilo; N-(4-aminobutil)carbamoilo o R4 es unasecuencia de 1 a 6 aminoácidos ouna amida del mismo y sus sales aceptables en términos farmacéuticos y las composiciones farmacéuticas que los contienen.
ARP970100731A 1996-02-23 1997-02-21 Derivado peptido; composicion farmaceutica que contiene para tratar enfermedades; el uso del derivado peptido. AR005974A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9603855.9A GB9603855D0 (en) 1996-02-23 1996-02-23 Peptide derivatives
GBGB9620819.4A GB9620819D0 (en) 1996-10-05 1996-10-05 Chemical compounds

Publications (1)

Publication Number Publication Date
AR005974A1 true AR005974A1 (es) 1999-07-21

Family

ID=26308795

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970100731A AR005974A1 (es) 1996-02-23 1997-02-21 Derivado peptido; composicion farmaceutica que contiene para tratar enfermedades; el uso del derivado peptido.

Country Status (28)

Country Link
US (1) US6087336A (es)
EP (1) EP0882066B1 (es)
JP (1) JP3468528B2 (es)
KR (1) KR19990087123A (es)
CN (1) CN1116305C (es)
AR (1) AR005974A1 (es)
AT (1) ATE196152T1 (es)
AU (1) AU722877C (es)
BR (1) BR9707720A (es)
CA (1) CA2242809A1 (es)
CZ (1) CZ266398A3 (es)
DE (1) DE69703032T2 (es)
DK (1) DK0882066T3 (es)
ES (1) ES2151716T3 (es)
GB (1) GB9702377D0 (es)
GR (1) GR3034361T3 (es)
HR (1) HRP970099B1 (es)
HU (1) HU222198B1 (es)
ID (1) ID16037A (es)
IL (1) IL125804A0 (es)
NO (1) NO983849L (es)
NZ (1) NZ330944A (es)
PL (1) PL328486A1 (es)
PT (1) PT882066E (es)
SK (1) SK114998A3 (es)
TR (1) TR199801614T2 (es)
TW (1) TW492978B (es)
WO (1) WO1997031023A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702377D0 (en) * 1996-02-23 1997-03-26 Zeneca Ltd Peptide derivatives
TR199802537T2 (xx) * 1996-06-07 1999-03-22 Zeneca Limited Peptit t�revleri.
GB9621836D0 (en) 1996-10-19 1996-12-11 Zeneca Ltd Peptide compounds
GB9624562D0 (en) * 1996-11-27 1997-01-15 Zeneca Ltd Peptide derivatives
GB9625865D0 (en) * 1996-12-12 1997-01-29 Zeneca Ltd Peptides
GB9809021D0 (en) 1998-04-29 1998-06-24 Zeneca Ltd Chemical process
AU1926700A (en) * 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase
US6262080B1 (en) 1998-12-31 2001-07-17 Avantis Pharmaceuticals Inc. 3-(thio-substitutedamido)-lactams useful as inhibitors of matrix metalloproteinase
GB9912911D0 (en) * 1999-06-04 1999-08-04 Zeneca Ltd Chemical process
US6485740B1 (en) * 2000-03-14 2002-11-26 Yutoku Pharmaceutical Ind., Co., Ltd. Transdermal methotrexate preparations
GB0017979D0 (en) * 2000-07-22 2000-09-13 Astrazeneca Ab Chemical process
GB0130285D0 (en) 2001-12-19 2002-02-06 Astrazeneca Ab Chemical process
GB0130286D0 (en) * 2001-12-19 2002-02-06 Astrazeneca Ab Chemical process
GB0317733D0 (en) 2003-07-29 2003-09-03 Novartis Ag Organic compounds
EP2366448B1 (en) * 2010-03-16 2016-07-27 Amminex Emissions Technology A/S Method and device for controlled dosing of a gas with fluctuating supply pressure
ES2874525T3 (es) * 2012-09-26 2021-11-05 Harvard College Péptidos grapados bloqueados con prolina y usos de los mismos

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474778A (en) * 1983-11-09 1984-10-02 E. R. Squibb & Sons, Inc. Lactam containing compounds, their pharmaceutical compositions and method of use
US4680283A (en) * 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin
DE3711335A1 (de) * 1987-04-03 1988-10-20 Merck Patent Gmbh Aminosaeurederivate
US5331089A (en) * 1988-03-25 1994-07-19 Merck Sharpe & Dohme, Ltd. Peptides useful as tachykinin agonists
EP0360390A1 (en) * 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5223485A (en) * 1989-01-31 1993-06-29 Abbott Laboratories Anaphylatoxin-receptor ligands
AU8305491A (en) * 1990-08-01 1992-03-02 Cytel Corporation Novel immunosuppressant peptides
DE4034829A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh Cyclopeptide
AU2468392A (en) * 1991-08-29 1993-04-05 Cytel Corporation Novel immunosuppressants
JPH0725887A (ja) * 1993-06-04 1995-01-27 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
AU698962B2 (en) * 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
CA2186873A1 (en) * 1994-04-01 1995-10-12 Charles J. Hackett Haptenated peptides and uses thereof
DE69615671T2 (de) * 1995-03-24 2002-08-08 Molecumetics, Ltd. Beta-schleifenähnliche verbindungen und deren verwendung als protease-inhibitoren
WO1997016425A1 (en) * 1995-10-30 1997-05-09 Merck & Co., Inc. Novel inhibitors of peptide binding to mhc class ii proteins
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
GB9702377D0 (en) * 1996-02-23 1997-03-26 Zeneca Ltd Peptide derivatives

Also Published As

Publication number Publication date
CZ266398A3 (cs) 1998-11-11
DK0882066T3 (da) 2000-12-18
PT882066E (pt) 2000-12-29
AU722877C (en) 2002-12-05
HU222198B1 (hu) 2003-05-28
EP0882066B1 (en) 2000-09-06
AU1803597A (en) 1997-09-10
ATE196152T1 (de) 2000-09-15
EP0882066A1 (en) 1998-12-09
DE69703032T2 (de) 2001-04-12
DE69703032D1 (de) 2000-10-12
CN1213379A (zh) 1999-04-07
HRP970099B1 (en) 2001-10-31
HUP9901189A3 (en) 2000-07-28
ES2151716T3 (es) 2001-01-01
NO983849L (no) 1998-10-21
KR19990087123A (ko) 1999-12-15
HUP9901189A2 (hu) 1999-08-30
TW492978B (en) 2002-07-01
CA2242809A1 (en) 1997-08-28
WO1997031023A1 (en) 1997-08-28
PL328486A1 (en) 1999-02-01
GB9702377D0 (en) 1997-03-26
NZ330944A (en) 2000-04-28
US6087336A (en) 2000-07-11
GR3034361T3 (en) 2000-12-29
TR199801614T2 (xx) 1998-11-23
JP2000508623A (ja) 2000-07-11
CN1116305C (zh) 2003-07-30
JP3468528B2 (ja) 2003-11-17
HRP970099A2 (en) 1998-04-30
SK114998A3 (en) 1999-02-11
NO983849D0 (no) 1998-08-21
BR9707720A (pt) 1999-04-06
IL125804A0 (en) 1999-04-11
AU722877B2 (en) 2000-08-10
HK1015383A1 (en) 1999-10-15
ID16037A (id) 1997-08-28

Similar Documents

Publication Publication Date Title
AR005974A1 (es) Derivado peptido; composicion farmaceutica que contiene para tratar enfermedades; el uso del derivado peptido.
Sternbach The benzodiazepine story
FI118336B (fi) Uudet delta-amino-gamma-hydroksi-omega-aryylialkaanihappoamidit, niitä sisältävät farmaseuttiset valmisteet, menetelmiä niiden valmistamiseksi ja menetelmissä käyttökelpoiset välituotteet
CN1538951B (zh) 用作多形核和单核细胞趋化性抑制剂的R-2-芳基-丙酸的ω-氨烷基酰胺
MY102866A (en) Amide derivatives.
AR035518A1 (es) Derivados de carboxamida, un procedimiento para su preparacion, un medicamento que los contiene, el u so de los mismos para preparar un medicamento, y un conjunto (kit) que los incluye
BRPI0616755A2 (pt) compostos de carboxiamina e métodos de uso dos mesmos
NZ332347A (en) Peptide derivatives containing a hydrophobic group, L-amino acid residues and modified L-amino acid residues
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
JP2011526620A (ja) プロテアソームモジュレーターとしての窒素複素環誘導体
ATE4980T1 (de) Morpholinderivate, sie enthaltende pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung.
LV5794A4 (lv) Nonapeptidi ar bombezina antagonistu ipasibam
TWI232220B (en) Thienopyrimidines
NO152047C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksom 5-(paradeuterofenyl)-5-fenylhydantoin
PE20010117A1 (es) Derivados monofluoroalquilo que potencian la funcion de los receptores de glutamato
Rosen et al. Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist
DE3762860D1 (de) 2-thiazolylimidazo(1,2-a)pyrimidine und ihre salze, verfahren zu ihrer herstellung, ihre anwendung als arzneimittel und diese enthaltende zubereitungen.
US5272175A (en) Substituted tyrosyl diamide compounds
CY1110613T1 (el) Υποκατεστημενες θειαζολες και η χρησιμοποιηση τους για την παρασκευη φαρμακων
US4873241A (en) 2-amino-N-(2-phenylindan-2-yl)acetamides useful as anti-epileptics
MX9405110A (es) Nuevos derivados de (1-heteroazolil-1-heterociclil)alcano y su uso comoagentes neuroprotectores.
ES2135695T3 (es) Derivados de aminoacidos y su uso como inhibidores de la fosfolipasa a2.
FI963440A0 (fi) Uudet aminohappojohdannaiset, näiden valmistusmenetelmä ja näitä yhdisteitä sisältävät farmaseuttiset seokset
MXPA05003113A (es) Pequenas moleculas organicas que aumentan la actividad de gelatinasa en celulas oculares.
US20110257176A1 (en) Nitrogen heterocycle derivatives as proteasome modulators

Legal Events

Date Code Title Description
FA Abandonment or withdrawal